Gilead’s RA Hopeful Filgotinib Hit By Complete Response Letter
FDA Concerned About High Dose And Testicular Side Effects
Executive Summary
Complete Response Letter is a major setback for Gilead and its partner Galapagos.
You may also be interested in...
MANTA Brings Glimmer Of Good News To Galapagos
After a difficult spell for the Belgian biotech, positive interim data from two key studies looking at testicular toxicity concerns over filgotinib suggest a pathway for potential future US approval of the Gilead-partnered JAK inhibitor for IBD.
Ziritaxestat Failure Could Spell End For Gilead/Galapagos Pact
The Galapagos and Gilead partnership has had a tough few months and the failure of ziritaxestat, plus the decision not to develop filgotinib Stateside for rheumatoid arthritis, is calling into question the merits of the whole collaboration for the US biotech.
Galapagos CEO Upbeat Despite Filgotinib Upset In US
Onno van de Stolpe has told Scrip it will take time to win investor confidence back after more disappointing news about the JAK inhibitor but Galapagos has "the pipeline and the cash in the organization to do so."